This event is dedicated to fostering partnerships and collaboration amongst industry, governments, payers, investors and patients. It is about expediting orphan drug development and articulating its value, from discovery to patient access, so that manufacturers are guaranteed full and speedy reimbursement.
Publish your white paper on our dedicated Total Orphan Drugs blog, monthly newsletter
Dedicated email blast to targeted job titles and profiles
20-minute plenary keynote or case study
Chair a whole day at the main conference, Rare Disease Advocacy World or Pitch & Partner
20-minute plenary keynote
Moderate a round table discussion
Host a cocktail hour
Throw a dinner party
Sponsor breakfast, coffee breaks or lunch
Book either a 60, 120 or 240 square feet space
Wrap your brand around a column at the World Orphan Drug Congress USA Exhibit Hall
- 2015 Conference Attendee
Showcase your expertise by joining our impressive speaker line-up.
In 2015 we were joined by:
"The most comprehensive event I've attended in the past few years. It was the perfect opportunity for learning all the latest important information in the rare disease space."
Patricia Weltin, Executive Director and Founder, Rare Disease United Foundation
"The congress was extremely stimulating and productive for us: If there was a prize for phenomenal energy, good vibes, and flawless execution, you and your folks would win it, hands down."
Florian Brey, Medical Director, JUICE Pharma Worldwide
"Amazing collaborative environment and networking. Great Orphan 360-degree perspective. Very informative compact event."
Oksana Komarova, Business Development Director, Big Arrow Group
With a little over 3 months to go until the inaugural World Anti-Microbial Resistance Congress, we’ve been busy putting the finishing touches to the conference agenda. ...
The post Should we talk about orphan drug designation for AMR antibiotics? appeared first on Orphan Drugs.
Chris Cashman of Marinus Pharmaceuticals Inc. joined us for World Orphan Drug Conference USA 2015 to present about ‘ Leading Innovation in Treatment of Epilepsy and Neuropsychiatric ...
The post “Leading Innovation in Treatment of Epilepsy and Neuropsychiatric Disorders” appeared first on Orphan Drugs.
Chris Adams of Andarix Pharmaceuticals joined us for World Orphan Drug Congress USA 2015 to present about ‘ Tozaride: Targeted & Personalized Therapy for Small Cell Lung ...
The post “Tozaride: Targeted & Personalized Treatment for Small Cell Lung and Neuroendocrine Cancer” appeared first on Orphan Drugs.
Strategy and innovation for the orphan drug and rare disease industry